NTLA

Intellia Therapeutics, Inc.

23.75 USD
-0.40 (-1.66%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Intellia Therapeutics, Inc. stock is down -8.55% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 88.89% of the previous 8 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 4 CALLs, 6 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
20 Jun 19:00 17 Jan, 2025 25.00 CALL 151 1649
20 Jun 19:03 17 Jan, 2025 25.00 CALL 108 1649
20 Jun 19:03 17 Jan, 2025 25.00 CALL 96 1649
20 Jun 19:03 17 Jan, 2025 25.00 CALL 231 1649
20 Jun 19:04 17 Jan, 2025 25.00 PUT 179 2388
20 Jun 19:05 17 Jan, 2025 25.00 PUT 126 2388
20 Jun 19:05 17 Jan, 2025 25.00 PUT 74 2388
20 Jun 19:05 17 Jan, 2025 25.00 PUT 93 2388
20 Jun 19:07 17 Jan, 2025 25.00 PUT 93 2388
20 Jun 19:09 17 Jan, 2025 25.00 PUT 54 2388

About Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis. The firm has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells.

  • Cantor Fitzgerald
    Tue Jun 18, 10:09
    buy
    confirm
  • Cantor Fitzgerald
    Tue Jun 4, 13:27
    buy
    confirm